Oruka Therapeutics, Inc.
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology conditions. Its programs target validated immune pathways, with ORKA-001 designed to target IL-23p19 and ORKA-002 designed to target IL-17A/F. Both candidates incorporate half-life extension technology. Oruka is also developing ORKA-021, a planned sequential regimen of ORKA-002 followed by ORKA-001, and ORKA-003, which targets an undisclosed pathway. Oruka’s business centers on developing these product candidates for potential use in psoriasis, hidradenitis suppurativa, psoriatic arthritis and other conditions. It holds royalty-bearing, worldwide, exclusive licenses from Paragon Therapeutics to develop, manufacture and commercialize specified antibodies and products for ORKA-001 and ORKA-002. Oruka Therapeutics is headquartered in Menlo Park, California.
No enriched coverage for $ORKA in the last 7 days.
Klein Lawrence Otto (Chief Executive Officer) sold 25,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $95.60 ($94.77–$98.40, $2.39M total) across 5 trades on 2026-11-02 under a Rule 10b5-1 trading plan.
Guggenheim reaffirmed a Buy rating on Oruka Therapeutics, setting a $200 price target, implying a 121.4% upside from the last close. The firm cited positive Phase IIb study results for ORKA-001, with a 61% PASI-100 response rate, and projected peak sales of $7 billion, indicating strong market potential.
Wedbush reaffirmed its Outperform rating and $165 price target for Oruka Therapeutics, implying 82.7% upside from the Oct 26 close. The firm cited positive Phase 2b trial data for ORKA-001 and strategic Phase 3 trial plans.
Recent ORKA coverage spans financial news, insider activity and technology.
In the last 30 days, ORKA insiders filed 19 SEC Form 4 transactions — no purchases and 19 sales ($4.4M). The most active reporter was Goncalves Joana, Chief Medical Officer, with 5 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale may create modest short‑term selling pressure.
Positive trial data and a $200 price target suggest strong upside potential.
Positive trial results suggest strong efficacy, likely driving share price higher.
Robust Phase 2b efficacy should drive further buying as the program moves toward Phase 3.
Positive Phase 2b data is likely to lift the stock as investors anticipate Phase 3 advancement.
AlphAI scores every news story that mentions ORKA with an AI model for sentiment and relevance, and aggregates insider trades from Oruka Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Klein Lawrence Otto (Chief Executive Officer) sold 25,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $95.60 ($94.77–$98.40, $2.39M total) across 5 trades on 2026-11-02 under a Rule 10b5-1 trading plan.
1 min readGuggenheim reaffirmed a Buy rating on Oruka Therapeutics, setting a $200 price target, implying a 121.4% upside from the last close. The firm cited positive Phase IIb study results for ORKA-001, with a 61% PASI-100 response rate, and projected peak sales of $7 billion, indicating strong market potential.
1 min readWedbush reaffirmed its Outperform rating and $165 price target for Oruka Therapeutics, implying 82.7% upside from the Oct 26 close. The firm cited positive Phase 2b trial data for ORKA-001 and strategic Phase 3 trial plans.
2 min readSurgery Partners (SGRY) rose 48% on $6B buyout talks with Bon Secours Mercy Health. Xencor (XNCR) gained 17% on positive Phase 1 kidney cancer data. Oruka (ORKA) jumped 12% after strong Phase 2b psoriasis results. Acumen (ABOS) rose 19% ahead of November Alzheimer's trial readout.
2 min readOruka Therapeutics (ORKA) reported positive Phase 2b results for ORKA-001, showing 61% PASI 100 and 86% PASI 90 response rates in psoriasis patients. The trial enrolled 187 patients. ORKA-001 is a monoclonal antibody targeting IL-23p19. The company plans Phase 3 trials in 2027. ORKA stock is up 7.00% to $85.76.
2 min readOruka Therapeutics, Inc. (ORKA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tol
2 min readOruka Therapeutics' (ORKA) General Counsel, Paul T. Quinlan, sold 9,000 shares for $706,734, following a 10b5-1 plan. Shares have risen 189% in a year but are deemed overvalued. Quinlan previously exercised warrants for 9,000 shares at $7.80 each. ORKA reported positive trial results for ORKA-001, with Piper Sandler and H.C. Wainwright maintaining bullish ratings and targets of $180 and $120, respectively.
2 min readQuinlan Paul T (General Counsel) sold 9,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $78.53 ($74.90–$79.49, $0.71M total) across 5 trades on 2026-10-20 under a Rule 10b5-1 trading plan.
1 min readBTIG maintained a Buy rating on Oruka Therapeutics with a $151 price target, suggesting a 109.9% upside from the Oct 16 close of $71.93. The firm highlights strong clinical data for ORKA-001 and market potential for ORKA-002 in treating inflammatory conditions.
1 min readOruka Therapeutics' CMO Joana Goncalves sold $523,647 in stock at $73.89-$77.71 per share, per a 10b5-1 plan. She also acquired 7,000 shares via options/warrants. ORKA stock rose 165% year-over-year, with a $5.08B market cap. Analysts maintain Buy/Overweight ratings, citing trial results and pipeline strength, despite recent price declines.
1 min read
